{"DataElement":{"publicId":"5975732","version":"1","preferredName":"Prostate Gland Malignant Neoplasm Classification Type","preferredDefinition":"The subtype of prostate malignancy which can  be obtained by the PAM50 gene expression.","longName":"PROSTATE_CANCER_SUBTYPE","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"5894806","version":"1","preferredName":"Prostate Gland Malignant Neoplasm Subtype Classification","preferredDefinition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen._Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._A group forming a type within a larger type._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"2320019v1.0:5894804v1.0","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2320019","version":"1","preferredName":"Prostate","preferredDefinition":"A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS)","longName":"C12410","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Gland","conceptCode":"C12410","definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC6EF0D8-50A9-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5894804","version":"1","preferredName":"Malignant Neoplasm Subtype Classification","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:A group forming a type within a larger type.:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"C14143:C3262:C25696:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"536D5FEA-D2DF-17C7-E053-F662850A1007","latestVersionIndicator":"Yes","beginDate":"2017-07-03","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-07-03","modifiedBy":"ONEDATA","dateModified":"2017-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"536D5FEA-D2F0-17C7-E053-F662850A1007","latestVersionIndicator":"Yes","beginDate":"2017-07-03","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-07-03","modifiedBy":"WELSHE","dateModified":"2017-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5975725","version":"1","preferredName":"Prostate Cancer Molecular Subtype Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"5975725v1.0","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Luminal A Prostate Carcinoma","valueDescription":"Luminal A Prostate Carcinoma","ValueMeaning":{"publicId":"5975726","version":"1","preferredName":"Luminal A Prostate Carcinoma","longName":"5975726","preferredDefinition":"Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a lower proliferation score than the luminal B and basal-like prostate carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luminal A Prostate Carcinoma","conceptCode":"C138168","definition":"Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a lower proliferation score than the luminal B and basal-like prostate carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-D01D-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58B03C6C-D036-5B3B-E053-F662850A0A30","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"ONEDATA","dateModified":"2017-09-08","deletedIndicator":"No"},{"value":"Luminal B Prostate Carcinoma","valueDescription":"Luminal B Prostate Carcinoma","ValueMeaning":{"publicId":"5975727","version":"1","preferredName":"Luminal B Prostate Carcinoma","longName":"5975727","preferredDefinition":"Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a higher proliferation score than the luminal A prostate carcinoma. Patients with luminal B prostate carcinoma have the poorest prognosis but respond better to postoperative androgen deprivation therapy compared to patients with nonâ€“luminal B prostate carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luminal B Prostate Carcinoma","conceptCode":"C138169","definition":"Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a higher proliferation score than the luminal A prostate carcinoma. Patients with luminal B prostate carcinoma have the poorest prognosis but respond better to postoperative androgen deprivation therapy compared to patients with non-luminal B prostate carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-D042-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58B03C6C-D05B-5B3B-E053-F662850A0A30","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"ONEDATA","dateModified":"2017-09-08","deletedIndicator":"No"},{"value":"Basal-Like Prostate Carcinoma","valueDescription":"Basal-Like Prostate Carcinoma","ValueMeaning":{"publicId":"5975728","version":"1","preferredName":"Basal-Like Prostate Carcinoma","longName":"5975728","preferredDefinition":"Prostate carcinoma in which the CD49f signature is increased, the luminal markers and androgen receptor expression and signaling (androgen activity pathway) are not increased, and the proliferation score is higher than the luminal A prostate carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basal-Like Prostate Carcinoma","conceptCode":"C138170","definition":"Prostate carcinoma in which the CD49f signature is increased, the luminal markers and androgen receptor expression and signaling (androgen activity pathway) are not increased, and the proliferation score is higher than the luminal A prostate carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-D067-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58B03C6C-D080-5B3B-E053-F662850A0A30","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"ONEDATA","dateModified":"2017-09-08","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2960664","version":"1","preferredName":"Unknown","longName":"2960664","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78485FBD-4C65-D67B-E040-BB89AD432E0E","latestVersionIndicator":"Yes","beginDate":"2009-11-13","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-11-13","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAE3FD6-A640-7956-E053-F662850A618E","beginDate":"2017-10-16","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435028","version":"1","preferredName":"Gene Product","preferredDefinition":"A protein or RNA whose structure is represented in and determined by genomic sequences.","longName":"C26548","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-8320-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-D006-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"WELSHE","dateModified":"2017-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PAM50 Molecular Subtype","type":"Preferred Question Text","description":"PAM50 Molecular Subtype","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-D08A-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"WELSHE","dateModified":"2017-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}